The results here demonstrate initially that BBI608 can significantly suppress the persistent Stat3 activation signalling pathway and can promote the effects exerted by paclitaxel on epithelial ovarian cancer in vivo and in vitro by downregulating gene products that mediate tumour cell proliferation, metastasis, invasion and survival. Here, STAT3 is linked to neoplasm.